Glucagon-like peptide-1 receptor (GLP1R) agonists, GLP1 analogues that are resistant to degradation by dipeptidyl peptidase 4, are used to treat type 2 diabetes mellitus (T2DM) [1]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.